lifestyle.onlygolfnews.com

Author: RIGEL PHARMACEUTICALS, INC.

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

May 12, 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

May 12, 2026
Rigel Reports First Quarter 2026 Financial Results

May 5, 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

April 28, 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

March 31, 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

February 24, 2026
Rigel Appoints Michael P. Miller to the Board of Directors

February 3, 2026
Rigel Provides Business Update and 2026 Outlook

January 12, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

January 9, 2026
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026